<DOC>
	<DOCNO>NCT01584544</DOCNO>
	<brief_summary>This phase I study design determine maximum tolerant dose capecitabine use preoperative concurrent chemo-radiation locally advanced rectal patient 75 year old .</brief_summary>
	<brief_title>Safety Study Capecitabine With Radiation Elderly Rectal Cancer</brief_title>
	<detailed_description>It prove preoperative concurrent chemo-radiotherapy improve local control overall survival stage II/III rectal cancer patient . But elderly patient , especially patient 75 year hardly involve related clinical trial consider fragility . Several retrospective study show old rectal cancer patient would also benefit concurrent chemo-radiation , acceptable toxicity . Several new drug , capecitabine , also seem safety elderly cancer patient . But prospective study carry . The investigator design phase I study , explore maximum tolerant dose capecitabine preoperative concurrent chemoradiation elderly stage II/III rectal cancer patient , well evaluate safety .</detailed_description>
	<mesh_term>Rectal Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<criteria>rectal adenocarcinoma , clinical stage II/III ( T34 N+ , AJCC 7th ) . KPS status le 70 ; Charlson comorbidity 3. life expectancy 6 month . hemoglobin &gt; = 100g/L , white blood cell &gt; = 3.5*10E9/L , neutrophil &gt; = 1.5*10E9/L , platelet &gt; = 100*10E9/L.Creatin normal , Total bilirubin normal , AST AST normal , AKP normal . allergy history thymidine phosphorylase . receive surgery ( except palliative colostomy ) chemotherapy anticancer treatment previously pelvic irradiation history inform consent sign cancer history , except curable nonmelanoma skin cancer cervix insitu carcinoma previous pelvic irradiation history receive surgery ( except palliative colostomy ) , chemotherapy anticancer treatment allergy history thymidine phosphorylase active infection exist severe complication , acute myocardial infarction 6 month , uncontrolled diabetes ( Plasma glucose concentration time day≥11.1mmol/L） , severe cardiac arrhythmia， etc . anticipate clinical trial four week enrollment</criteria>
	<gender>All</gender>
	<minimum_age>75 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>rectal neoplasm</keyword>
	<keyword>age</keyword>
	<keyword>chemoradiotherapy</keyword>
	<keyword>clinical trial , phase I</keyword>
	<keyword>capecitabine</keyword>
</DOC>